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Abstract
Rare single-gene disorders cause chronic disease. However, half of the 6,000 recessive single gene
causes of disease are still unknown. Because recessive disease genes can illuminate, at least in
part, disease pathomechanism, their identification offers direct opportunities for improved clinical
management and potentially treatment. Rare diseases comprise the majority of chronic kidney
disease (CKD) in children but are notoriously difficult to diagnose. Whole exome resequencing
facilitates identification of recessive disease genes. However, its utility is impeded by the large
number of genetic variants detected. We here overcome this limitation by combining
homozygosity mapping with whole exome resequencing in 10 sib pairs with a nephronophthisis-
related ciliopathy, which represents the most frequent genetic cause of CKD in the first three
decades of life. In 7 of 10 sib-ships with a histologic or ultrasonographic diagnosis of
nephronophthisis-related ciliopathy we detect the causative gene. In six sib-ships we identify
mutations of known nephronophthisis-related ciliopathy genes, while in two additional sib-ships
we found mutations in the known CKD-causing genes SLC4A1 and AGXT as phenocopies of
nephronophthisis-related ciliopathy. Thus whole exome resequencing establishes an efficient, non-
invasive approach towards early detection and causation-based diagnosis of rare kidney diseases.
This approach can be extended to other rare recessive disorders, thereby providing accurate
diagnosis and facilitating the study of disease mechanisms.
INTRODUCTION
Rare recessive diseases cause chronic diseases that often require hospitalization.1 For
example, rare chronic kidney diseases (CKD) comprise the majority of cases treated within
chronic dialysis and renal transplantation programs in the first 3 decades of life, but are
notoriously difficult to diagnose.2 However, the genetic basis of approximately half of
recessive diseases including CKD is still unknown (http://omim.org/statistics/entries). As
recessive mutations represent directly the primary disease cause, gene identification offers a
powerful approach to revealing disease mechanisms in such disorders. Furthermore, because
recessive mutations predominantly convey loss of function, recessive single-gene defects
can be transferred directly into animal models, to study the related disease mechanisms and
to screen for small molecules as possible treatment modalities.
Nephronophthisis (NPHP) is a recessive cystic kidney disease that represents the most
frequent genetic cause of CKD in the first three decades of life. NPHP-related ciliopathies
(NPHP-RC) are typically recessive single-gene disorders that affect kidney, retina, brain and
liver by prenatal-onset dysplasia or by organ degeneration and fibrosis in early adulthood.3
Ultrasonographically, NPHP are characterized by increased echogenicity and cyst formation
at the corticomedullary junction in small or normal-sized kidneys (Figure 1).4 And renal
histology exhibits a characteristic triad of renal corticomedullary cysts, tubular basement
membrane disruption, and tubulointerstitial inflitrations.5 Regarding renal, retinal and
hepatic involvement there is phenotypic overlap of NPHP-RC with Bardet-Biedl syndrome
(BBS).6 Identification of recessive mutations in 15 different genes (NPHP1-NPHP15)7–20
revealed that the encoded proteins share localization at the primary cilia-centrosomes
complex, characterizing them as retinal-renal “ciliopathies”.3, 21 However, the 15 known
NPHP-RC genes explain less than 50% of all cases with NPHP-RC, indicating that many of
the genetic causes of NPHP-RC are still elusive.22, 23
Some of the more recently identified genetic causes of NPHP-RC are exceedingly rare.15
This observation necessitates a strategy to identify additional genetic causes of NPHP-RC in
single affected families. In this context whole exome capture with consecutive massively
parallel sequencing, (here referred to as whole exome resequencing, WER), theoretically
offers a powerful approach towards gene identification in rare recessive diseases.24
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However, the utility of WER is hampered by the large number of genetic variants that result
from whole exome sequencing in any given individual.18, 25
To overcome the difficulty of variant prioritization in WER, we developed a strategy that
combines WER18 with homozygosity mapping.26 We here apply this approach to 10
families with siblings with the diagnosis of “NPHP-RC”, based on clinical, renal
sonographic, and/or histologic findings. Using this strategy we identified the primary
causative mutations in 7 of the 10 sib pairs (70%). In six families we detect mutations of
known NPHP-RC genes. In two additional families we revise the erroneous clinical
diagnosis of NPHP-RC through identification of mutations in SLC4A1 and AGXT. This
established the correct diagnoses of distal renal tubular acidosis and hyperoxaluria,
respectively, which had appeared as clinical phenocopies of NPHP-RC.
We hereby establish a non-invasive molecular genetic approach towards early detection and
causation-based diagnosis of rare kidney diseases by applying WER and homozygosity
mapping to sibling cases. The approach is efficient and can be extended to all rare recessive
diseases, thereby facilitating the study of disease mechanisms.
RESULTS
Clinical features of sibs with an NPHP-RC phenotype
From over 500 families with a diagnosis on NPHP-RC that were referred to us from
worldwide sources for molecular genetic diagnosis we selected sibling cases with no known
primary mutations from 10 different families (Table 1). Inclusion criteria were a diagnosis
of NPHP-RC in both siblings based on renal ultrasonographic4 (Figure 1) and/or histologic5
findings characteristic for NPHP or a related ciliopathy. Many cases had extrarenal
symptoms typical for NPHP-RC, including retinitis pigmentosa and neurologic involvement
(Table 1).
Homozygosity mapping in 10 sibs with a diagnosis of NPHP-RC
The finding that most of the known NPHP-RC genes (NPHP2-NPHP13) contribute
causative mutations in only a small number of cases each (<1–3%)15 necessitates the ability
to map and identify disease-causing genes in single families. We therefore employed a
previously developed strategy,18, 26 that combines homozygosity mapping in single families
with WER. We performed genome wide homozygosity mapping in the 10 sibships with
NPHP-RC as described (see Figure S1).26 Eight families were known to be consanguineous
and two had no evidence for consanguinity (Table 1). Homozygosity mapping yielded
segments of likely homozygosity by descent (“homozygosity peaks”)26 in all eight families
with consanguinity, but in none of the two families (A2841 and F838) without
consanguinity (see Figure S1). This is consistent with our previous finding that individuals
with known consanguinity exhibit segments of homozygosity upon mapping, whereas
segments of homozygosity are rare in outbred families.26 In the eight consanguineous
families the number of homozygosity peaks ranged from one to fifteen (Table 1 and Figure
S1).
Mutations in six known NPHP-RC genes
Following homozygosity mapping and WER (Figure S1 and Table S1–S2), we identified
recessive mutations in the known ciliopathy genes INVS/NPHP2, NPHP4, BBS1, BBS9, and
ALMS1 in five families with multiple affected sibs with NHPH-RC (families A2204, A2557,
A2882, A2888, and A2841) respectively (Table 1, Figure 2 and Table S1). Individual
A2557-21 with a homozygous truncating mutation in NPHP4 had characteristic clinical
signs (Table 1) and renal ultrasound features (Figure 1a) of NPHP. Interestingly, individual
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A2557-31, who is a cousin of A2557-21 and has the same mutation, developed end-stage
kidney disease (ESKD) at 32 years. This late manifestation with ESKD beyond age 25 years
is unusual in NPHP. Individuals A2882-21 and -22, who both carry a mutation in BBS1,
presented with postaxial polydactyly and obesity. Mutations in ALMS1 cause Alström
syndrome of which clinical features include blindness, obesity, type 2 diabetes, renal
dysfunction, and hypertension. Individuals A2841-21 and -22, who have two truncating
compound heterozygous mutations in ALMS1, presented with obesity, insulin resistance,
retinitis pigmentosa and kidney enlargement which are consistent with the genetic findings.
Mutations in two known CKD genes phenocopy NPHP-RC
Surprisingly, in families F650 and A3254 we identified mutations in the known CKD-
causing genes SLC4A1 and AGXT1, respectively, that apparently represent phenocopies of
NPHP-RC (Table 1).First, renal biopsy performed in both male siblings of family F650 at 19
and 18 years of age, respectively, revealed the suspected diagnosis of NPHP-RC with cystic
tubular ectasia (Table 1). This diagnosis was supported by the findings of polyuria,
polydipsia, failure to thrive, coloboma of the eye, and metabolic acidosis, which was thought
to be secondary to renal failure from NPHP. Subsequent renal ultrasound performed at 35
and 34 years of age, respectively, also showed features characteristic of NPHP, including
increased echogenicity and corticomedullary cysts in kidneys of normal size (Figure 1c).
However, over the years both brothers developed requirement of oral bicarbonate
supplementation of 3 g/day. They did not develop terminal renal failure by the ages of 35
and 34 years, respectively, and this late age of onset is not typical of NPHP. In addition,
renal ultrasound showed increased echogenicity that was pronounced in the rims
surrounding the corticomedullary renal cysts and in the pyramids (Figure 1d), a feature
unusual for NPHP. Identification of a homozygous mutation that deletes a highly conserved
amino acid residue in SLC4A1, which encodes the anion exchange protein 1 (AE1), enabled
us to make the unexpected diagnosis of distal renal tubular acidosis (dRTA) (Table 1, Figure
2 and Table S1). Recessive mutations of SLC4A1 have been reported previously to cause
dRTA with and without red blood cell dysmorphology.27
In another family with two affected cousins, A3254 and A3255, we suspected infantile-onset
NPHP-RC (Table 1). Individual A3254 had end-stage kidney disease (ESKD) at three
months with small echogenic kidneys on renal ultrasound (Figure 1d). Individual A3255
developed ESKD at 3 months of age, had brain atrophy and developmental delay, and died
age 19 months. Both cousins displayed retinal pigmentation (Table 1). WER revealed a
homozygous mutation in AGXT which encodes alanine-glyoxylate transferase 1, thereby
establishing the diagnosis of hyperoxaluria type 1 (Table 1, Figure 1 and Table S1).28 Thus,
in both families, we established an accurate molecular diagnosis by WER, which was
previously incorrectly ascribed to NPHP-RC early in the disease course, even following
detailed evaluation by renal biopsy or ultrasound.
In family F93 with four children with NPHP-RC and typical renal ultrasonographic features
(Figure 1b), genetic mapping excluded the entire genome from linkage with a disease locus
with the exception of the PKHD1 locus (Figure S1h). Although no mutations were detected
in PKHD1 by WER, the mapping result implicates PKHD1 as the most likely causative
gene, which is known to cause autosomal recessive polycystic kidney disease (ARPKD).
The four affected children of family F93 had a phenotype unusual for ARPKD, because the
kidneys were not enlarged, and there was extrarenal involvement with retinal coloboma.
Finally, two additional families, F838 and A2059 were non-consanguineous (Table 1) and
did not yield homozygosity peaks upon genetic mapping (Figure S1i–j). In family F838 for
which both affected individuals had a renal ultrasound consistent with NPHP (Figure 1e) we
detected a heterozygous nonsense mutation in the ciliopathy gene INPP5E (Table 1 and
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Figure 2), but we were unable to detect any additional mutations in trans at the same locus.
Finally, we were unable to detect a likely primary causal locus in family A2059 (Table 1 and
Table S1). In addition, we examined variants in known ciliopathy genes in WER data of all
10 families. The included genes were NPHP1, INVS, NPHP3, NPHP4, IQCB1, CEP290,
GLIS2, RPGRIP1L, NEK8, SDCCAG8, TMEM67, TTC21B, WDR19, ZNF423, CEP164,
BBS1, BBS2, ARL6, BBS4, BBS5, MKSS, TTC8, BBS9, BBS10, TRIM32, BBS12, MKS1,
WDPCP, TMEM216, AHI1, and CCDC28B. However, we could not detect any additional
pathogenic variants in these genes in the seven solved and three unsolved cases.
Furthermore, we checked genomic structural variants including large deletions and insertion,
inversions, replacements, and translocations for the three unsolved cases based on WER, but
there was no significant structural abnormality observed.
Taken together, we identified the disease-causing gene in 7 of 10 (70%) sibships, suggesting
that homozygosity mapping with WER provides an efficient approach for molecular genetic
diagnostics in diseases such as NPHP-RC and other ciliopathies where there is broad genetic
locus heterogeneity.
DISCUSSION
Here, we demonstrate that WER, when combined with homozygosity mapping in sibling
cases, represents a high-yield approach towards identification of primary causal mutations in
rare recessive diseases. From our findings, we draw several conclusions: First, WER offers a
viable, non-invasive approach for molecular diagnosis of rare recessive diseases. Second,
however, to reduce the multitude of variants generated by WER, an a priori method to
restrict this number is still required. Here, we show that the study of sib cases and the use of
homozygosity mapping provides a robust solution to this problem. Third, using this
approach, we achieved a high success rate for disease gene identification of 70%. In
monogenic diseases about 85% of all recessive mutations are thought to reside within exons
and adjacent intronic regions29 which are target regions of WER, so mutations in deep
introns and promoter regions are not covered by WER. In addition, WER can miss a causal
variant because of inadequate coverage (e.g. poor capture or poor sequencing) or inaccurate
variant calling (e.g. a small but complex indel).30 Fourth, our study demonstrates that for
individuals with childhood-onset renal failure, clinical diagnosis, renal ultrasound, and even
renal histology represent relatively blunt diagnostic tools, which can be incapable of
establishing the correct diagnosis. In this setting WER offers a powerful, non-invasive, cost-
efficient diagnostic tool for arriving at a correct, unequivocal, etiology-based diagnosis.31
Fifth, rare, genetically heterogeneous chronic kidney diseases comprise the majority of cases
of CKD in children but are notoriously difficult to diagnose. The use of WER will be
beneficial for these individuals, because it will be possible to accurately assign them to
therapeutic studies in larger cohorts. Sixth, our approach of combining homozygosity with
WER can be applied to other rare recessive diseases. This may be of great clinical utility, as
rare recessive disorders together cause a very high percentage of chronic diseases that
require inpatient treatment in pediatrics. Finally, because WER reveals the major etiologic
cause of a disease, gene identification will facilitate the elucidation of altered biological
pathways, as well as the generation of animal models for testing of new treatment
modalities.
WER now costs about $1,000 each per sample from several providers due to the substantial
cost reductions associated with next-generation sequencing technologies. It usually takes
four to eight weeks to get WER data after samples are submitted. Then, another four to eight
weeks are required to analyze the WER data including alignments, variant filtering,
confirmation and segregation analysis by Sanger sequencing. Therefore, the overall process
usually takes at least two to three months. This is only valid when analysis of WER is
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combined with HM. When mapping data are not available, more time is necessary for
evaluation and there is no standard protocol to filter variants from WER. Many laboratories
are using their own way to filter variants and are evaluating WER differently. Therefore, to
use WER widely as a diagnostic tool, a standard analytic pipeline should be established.
MATERIALS AND METHODS
Study Participants
From worldwide sources we obtained blood samples, clinical and pedigree data following
informed consent from individuals with NPHP-RC and/or their parents. Approval for human
subjects’ research was obtained from the University of Michigan Institutional Review Board
and relevant local Review Boards. The diagnosis of NPHP-RC was made by (pediatric)
nephrologists based on standardized clinical32, 33 and renal ultrasound4 criteria. Renal
biopsies were evaluated by renal pathologists.5 Clinical data were obtained using a
standardized questionnaire (http://www.renalgenes.org). The presence of retinal
degeneration or neurologic involvement was evaluated by ophthalmologists and (pediatric)
neurologists, respectively. In about 500 different families with NPHP-RC we excluded
homozygous deletions of the NPHP1 gene. In a subset of these families we excluded
mutations in selected known NPHP-RC genes using an approach of high-throughput
mutation analysis.34, 35 The remaining 10 families with multiple affected siblings without a
molecular genetic diagnosis were entered into this study for homozygosity mapping and
WER.
Homozygosity mapping
For genome-wide homozygosity mapping26 the ‘Human Mapping 250k StyI’ array or the
‘Genome-wide Human SNP 6.0 Array’ from Affymetrix™ were utilized. Genomic DNA
samples were hybridized, and scanned using the manufacturer’s standard protocol at the
University of Michigan Core Facility (www.michiganmicroarray.com). Non-parametric
LOD scores were calculated using a modified version of the program GENEHUNTER
2.136, 37 through stepwise use of a sliding window with sets of 110 SNPs using the program
ALLEGRO.38 Genetic regions of homozygosity by descent (‘homozygosity peaks’) were
plotted across the genome as candidate regions for recessive genes (see Figure S1), as
described.18, 39 Disease allele frequency was set at 0.0001, and Caucasian marker allele
frequencies were used.
Whole exome resequencing (WER)
Exome enrichment was conducted following the manufacturer’s protocol for the
‘NimbleGen™ SeqCap EZ Exome v2’ beads (Roche NimbleGen Inc.). The kit interrogates a
total of approximately 30,000 genes (~330,000 CCDS exons). Massively parallel sequencing
was performed largely as described in Bentley et al.40 For ten WER samples included in this
study, the average of 118 million reads (100 bp) per each WER was obtained and the
average coverage on target regions (exons) was 42.3 ± 13.4. For detail see Online Methods
in Supplementary Material, available with the full text of this article at http://
www.nature.com/ki.
Mutation calling
Sequence reads were mapped to the human reference genome assembly (NCBI build 36/
hg18) using CLC Genomics Workbench™ (version 4.7.2) software (CLC bio, Aarhus,
Denmark) as described in Online Methods in Supplementary Material. Mutation calling was
performed in parallel with a team of geneticists/cell biologists, who had knowledge of the
clinical phenotypes and pedigree structure, as well as experience with homozygosity
Gee et al. Page 6
Kidney Int. Author manuscript; available in PMC 2014 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
mapping and exome evaluation. Because exon capture with subsequent massively parallel
sequencing yields too many variants from normal reference sequence (VRSs) to make a
confident decision regarding the disease-causing mutation of a single recessive disease-
causing gene18, 25, we devised a strategy of a priori reduction of VRSs (see Online Methods
(‘Filtering of variants from normal reference sequence’) and Table S1 in Supplementary
Material).18
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Images of representative renal ultrasound (RUS) and renal biopsy findings in
individuals with an initial diagnosis of “NPHP-RC”
(a) In A2557-21 with a mutation in NPHP4, RUS showed a normal-sized kidney with
increased echogenicity when compared to liver (L), corticomedullary cysts (CMC) and loss
of corticomedullary differentiation (CMD).
(b) In F93-29 with homozygosity mapping implicating the PKHD1 locus, RUS showed
normal sized kidneys with small CMC and diminished CMD.
(c) In both siblings, F650-21 (left panel) and F650-22 (right panel) with dRTA as indicated
by a mutation in SLC4A1, RUS exhibits increased echogenicity and CMC in normal sized
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kidneys with loss of CMD, which prompted the diagnosis of NPHP-RC early in the course
of disease.
(d) In A3254 (left panel) and A3255 (right panel) with the molecular diagnosis of
hyperoxaluria type 1 as indicated by a mutation in AGXT, RUS of A3255 exhibited CMC.
RUS of A3254 showed mild distention of the collecting ducts.
(e) Right kidneys of siblings F838-21 (left panel) and -22 (right panel) harboring a
heterozygous mutation in INPP5E exhibited CMC and increased echogenicity comparable
to liver (L) signal.
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Figure 2. Recessive mutations detected by WER in 10 sibling cases with an NPHP-RC phenotype
Families are listed in the same order as in Table 1. Family numbers (underlined), mutated
gene, altered nucleotides and amino acid changes are given above sequence traces. Wild
type control sequences are shown below mutated sequences. Codon triplets are underlined to
indicate reading frame. Non-coding sequence is in lower case. Mutated nucleotides are
denoted by an arrow head. All mutations were absent from >270 ethnically matched healthy
controls. Five families have mutations in the known ciliopathy genes INVS/NPHP2, NPHP4,
BBS1, BBS9, and ALMS1. Two families have mutations in known NPHP-RC phenocopying
genes (SLC4A1 and AGXT). In F838 a heterozygous mutation was detected in INPP5E.
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